LAG3 and hepatocellular carcinoma: Higher levels of LAG‐3 are associated with unfavorable prognosis and poor clinical outcome in different types of solid tumors and hematologic malignancies; including renal cell carcinoma, bladder cancer, breast cancer, CRC, hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, and follicular lymphoma.